In what can bring down the cost of insulin vaccines, scientists at the Institute of Microbial Technology (IMTECH), Chandigarh have developed indigenous technology that is equipped to produce protein-based medicines like insulin, streptokinase and hepatitis B vaccine.
For the aforementioned medicines, India is dependent on imported and patented technology. Significantly, India is home to the second largest population of diabetes and hepatitis B patients after China.
Presently hepatitis B vaccines ranges between Rs 45 (Serum Institute) and Rs 250 per paediatric dose of 10 microgram in 0.5ml. The cost of adult dose of 20 microgram is nearly double, reports TOI. While, Insulin costs varies from Rs 140 to Rs 325 per injection.
The newly developed system, known as fission yeast has the potential to produce these medicines at much lower cost. For hepatitis B and diabetics, India has patients around 40 million and over 66 million respectively.